News
In early trading on Tuesday, US stocks saw Gilead Sciences' share price rise by 0.5%, as the company's HIV pre-exposure prophylaxis, lenacapavir injection, received EU approval, requiring only two injections per year
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments